Taken together, we disclose that the p53/miR-149-3p/PDK2 signaling pathway can potentially be targeted in overcoming chemoresistant CRC upon DCA treatment, providing a potential strategy for CRC treatment from the angle of intervening in tumor metabolism (Fig. 7e). Here, PDK2 is linked to neoplasm.